Last $4.45 USD
Change Today +0.03 / 0.68%
Volume 52.1K
TLOG On Other Exchanges
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

tetralogic pharmaceuticals c (TLOG) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/15/14 - $14.75
52 Week Low
05/27/14 - $3.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tetralogic pharmaceuticals c (TLOG) Related Businessweek News

No Related Businessweek News Found

tetralogic pharmaceuticals c (TLOG) Details

TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical company in the United States. The company focuses on discovering and developing novel small molecule therapeutics that mimic novel second mitochondrial activator of caspases to cause or enable abnormal cells, which are resistant to the body’s immune system to self-destruct. Its clinical-stage product candidate, Birinapant, is in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The company’s clinical and pre-clinical programs comprise an ongoing Phase I/II clinical trial of birinapant as a single agent in various blood cancers; a Phase I/II completed clinical trial of birinapant administered with irinotecan in colorectal cancer; and a Phase I/II clinical trial of birinapant administered with conatumumab in ovarian cancer, as well as an intention to start Phase I clinical trial in hepatitis B virus. It has collaboration with Amgen, Inc. for exploring the combination of birinapant administered with Amgen’s TRAIL receptor agonist antibody, conatumumab. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

28 Employees
Last Reported Date: 08/5/14
Founded in 2001

tetralogic pharmaceuticals c (TLOG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $175.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $141.2K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $137.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $315.2K
Compensation as of Fiscal Year 2013.

tetralogic pharmaceuticals c (TLOG) Key Developments

TetraLogic Pharmaceuticals Corporation(NasdaqGM:TLOG) dropped from Russell 2000 Index

TetraLogic Pharmaceuticals Corporation will be removed from the Russell 2000 Index.

TetraLogic Pharmaceuticals Corporation(NasdaqGM:TLOG) dropped from Russell 3000 Index

TetraLogic Pharmaceuticals Corporation will be removed from the Russell 3000 Index.

TetraLogic Seeks Acquisitions

TetraLogic Pharmaceuticals Corporation (NasdaqGM:TLOG) will seek acquisitions. TetraLogic announced the pricing of its offering of $47 million in aggregate principal amount of convertible senior notes. TetraLogic estimates that the net proceeds from this offering will be approximately $44 million after deducting the initial purchasers' discounts and commissions and the estimated offering expenses, it intends to use the net proceeds to finance clinical and preclinical development activities for birinapant and suberohydroxamic acid phenyl ester (SHAPE), for potential future in-licensing and for working capital and general corporate purposes, which may include payment of interest and acquisitions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLOG:US $4.45 USD +0.03

TLOG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLOG.
View Industry Companies

Industry Analysis


Industry Average

Valuation TLOG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRALOGIC PHARMACEUTICALS C, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at